Clinical Trials · NCT02254291
A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 308
- Start date
- Oct 2014
- Locations
- 25 sites, Japan
- Primary endpoint
- Number of Treatment Emergent Adverse Events (TEAEs)